Amyloid beta-Peptides

• 

  Subject Areas on Research

  • "I know that my role is going to change": a mixed-methods study of the relationship between amyloid-β PET scan results and caregiver burden. 
  • 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. 
  • 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner. 
  • A Bayesian perspective on Biogen's aducanumab trial. 
  • A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression. 
  • A blood-based signature of cerebrospinal fluid Aβ1-42 status. 
  • A deficit in astroglial organization causes the impaired reactive sprouting in human apolipoprotein E4 targeted replacement mice. 
  • A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. 
  • A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation. 
  • A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation. 
  • APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice. 
  • APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1. 
  • APOE: The New Frontier in the Development of a Therapeutic Target towards Precision Medicine in Late-Onset Alzheimer's. 
  • Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. 
  • Absence of mutation in the beta-amyloid cDNAs cloned from the brains of three patients with sporadic Alzheimer's disease. 
  • Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. 
  • Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. 
  • Acyclovir or Aβ42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. 
  • Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis. 
  • Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. 
  • Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. 
  • Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. 
  • Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy. 
  • Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. 
  • Alzheimer's disease. Risky apolipoprotein in brain. 
  • Alzheimer’s disease: the new promise. 
  • Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides. 
  • Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity. 
  • Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. 
  • Amyloid precursor protein 96-110 and beta-amyloid 1-42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids. 
  • Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells. 
  • Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. 
  • Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease. 
  • Amyloid-associated depression: a prodromal depression of Alzheimer disease? 
  • Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus. 
  • Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time. 
  • Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. 
  • Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. 
  • An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. 
  • Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. 
  • Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. 
  • ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. 
  • ApoE mimetic improves pathology and memory in a model of Alzheimer's disease. 
  • Apolipoprotein E and Alzheimer disease. 
  • Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. 
  • Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex. 
  • Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. 
  • Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. 
  • Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease. 
  • Association of CSF CD40 levels and synaptic degeneration across the Alzheimer's disease spectrum. 
  • Association of Genetic Variants With Primary Open-Angle Glaucoma Among Individuals With African Ancestry. 
  • Association of Sleep and β-Amyloid Pathology Among Older Cognitively Unimpaired Adults. 
  • Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers. 
  • Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E. 
  • Avid binding of beta A amyloid peptide to its own precursor. 
  • Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas. 
  • Binding of IgG to amyloid beta A4 peptide via the heavy-chain hinge region with preservation of antigen binding. 
  • Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. 
  • Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice. 
  • Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. 
  • CSF biomarker changes precede symptom onset of mild cognitive impairment. 
  • Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4. 
  • Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. 
  • Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. 
  • Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. 
  • Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. 
  • Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts. 
  • Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. 
  • Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. 
  • Conformational dynamics of amyloid beta-protein assembly probed using intrinsic fluorescence. 
  • Consequences of inhibiting amyloid precursor protein processing enzymes on synaptic function and plasticity. 
  • Continuity of care (COC) and amyloid-β PET scan: the CARE-IDEAS study. 
  • Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease. 
  • Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. 
  • Cupric-amyloid beta peptide complex stimulates oxidation of ascorbate and generation of hydroxyl radical. 
  • Current status of metals as therapeutic targets in Alzheimer's disease. 
  • Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. 
  • Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. 
  • Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension. 
  • Distribution of amyloid precursor protein and amyloid-beta in ocular hypertensive C57BL/6 mouse eyes. 
  • Does epileptiform activity contribute to cognitive impairment in Alzheimer's disease? 
  • Does increased platelet release of Abeta peptide contribute to brain abnormalities in individuals with depression? 
  • Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. 
  • Effect of acid predissolution on fibril size and fibril flexibility of synthetic beta-amyloid peptide. 
  • Effects of repetitive exposure to anesthetics and analgesics in the Tg2576 mouse Alzheimer's model. 
  • Elevation in plasma Abeta42 in geriatric depression: a pilot study. 
  • Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice. 
  • Enzymatic generation of the amino terminus of the beta-amyloid peptide. 
  • Exploration of the Potential Role for Aβ in Delivery of Extracellular Copper to Ctr1. 
  • Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition. 
  • Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. 
  • Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. 
  • Functional selection of protease inhibitory antibodies. 
  • Further understanding the connection between Alzheimer's disease and Down syndrome. 
  • Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. 
  • Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. 
  • Genetic susceptibility to Alzheimer disease. 
  • Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease. 
  • How Accurately Do Patients and Their Care Partners Report Results of Amyloid-β PET Scans for Alzheimer's Disease Assessment? 
  • Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. 
  • Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. 
  • Human apolipoprotein E2 promotes parenchymal amyloid deposition and neuronal loss in vasculotropic mutant amyloid-β protein Tg-SwDI mice. 
  • Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. 
  • Human apolipoprotein E4 targeted replacement mice show increased prevalence of intracerebral hemorrhage associated with vascular amyloid deposition. 
  • Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. 
  • Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. 
  • Iatrogenic Alzheimer Disease? Amyloid-β Protein Transmission Between Humans. 
  • Immunotherapy of malignant brain tumors. 
  • Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. 
  • Impact of APOE genotype on prion-type propagation of tauopathy. 
  • Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. 
  • Impaired thermoregulation and beneficial effects of thermoneutrality in the 3×Tg-AD model of Alzheimer's disease. 
  • In vivo amyloid imaging in Alzheimer's disease. 
  • In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. 
  • Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. 
  • Increased expression of p130 in Alzheimer disease. 
  • Inhibition of the NFAT pathway alleviates amyloid β neurotoxicity in a mouse model of Alzheimer's disease. 
  • Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. 
  • Interleukin-1 stimulates the beta-amyloid precursor protein promoter. 
  • Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. 
  • Is amyloid beta-protein glycated in Alzheimer's disease? 
  • MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders. 
  • Medicine. Old drug, new hope for Alzheimer's disease. 
  • Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. 
  • Metabolic network failures in Alzheimer's disease: A biochemical road map. 
  • Microglial contribution to oxidative stress in Alzheimer's disease. 
  • Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation. 
  • Mild cognitive impairment and asymptomatic Alzheimer disease subjects: equivalent β-amyloid and tau loads with divergent cognitive outcomes. 
  • Mitochondrial DNA sequence associations with dementia and amyloid-β in elderly African Americans. 
  • Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. 
  • Monitoring β-secretase activity in living cells with a membrane-anchored FRET probe. 
  • Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. 
  • NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. 
  • Neuroimaging and the search for a cure for Alzheimer disease. 
  • Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). 
  • Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1. 
  • No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. 
  • Non-cholinergic strategies for treating and preventing Alzheimer's disease. 
  • Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease. 
  • Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy. 
  • Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model. 
  • PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. 
  • Plasma Amyloid Beta Concentrations in Aged and Cognitively Impaired Pet Dogs. 
  • Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers. 
  • Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives. 
  • Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. 
  • Protein amyloidose misfolding: mechanisms, detection, and pathological implications. 
  • REST and stress resistance in ageing and Alzheimer's disease. 
  • Radical changes in beta-amyloid form and function. 
  • Rapid, scalable assay of amylin-β amyloid co-aggregation in brain tissue and blood. 
  • Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. 
  • Recent advances in the neurochemical pathology of Alzheimer's disease. Studies of neuropeptides, cholinergic function and Alzheimer's disease-associated protein. 
  • Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. 
  • Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. 
  • Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. 
  • Retinal microvasculature changes in amyloid-negative subcortical vascular cognitive impairment compared to amyloid-positive Alzheimer's disease. 
  • Sea urchin embryonic development provides a model for evaluating therapies against beta-amyloid toxicity. 
  • Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation. 
  • Serum triglycerides in Alzheimer disease: Relation to neuroimaging and CSF biomarkers. 
  • Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. 
  • Sex-specific genetic predictors of Alzheimer's disease biomarkers. 
  • Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. 
  • Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. 
  • Statins and cognition: what can we learn from existing randomized trials? 
  • Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. 
  • Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. 
  • Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. 
  • Tau is essential to beta -amyloid-induced neurotoxicity. 
  • Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. 
  • The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice. 
  • The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. 
  • The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer's Disease. 
  • The Effect of Propofol Versus Isoflurane Anesthesia on Human Cerebrospinal Fluid Markers of Alzheimer's Disease: Results of a Randomized Trial. 
  • The distribution of cerebrovascular amyloid in Alzheimer's disease varies with ApoE genotype. 
  • The mouse homolog of the human amyloid beta protein (AD-AP) gene is located on the distal end of mouse chromosome 16: further extension of the homology between human chromosome 21 and mouse chromosome 16. 
  • The release of Alzheimer's disease beta amyloid peptide is reduced by phorbol treatment. 
  • Transcriptomics Profiling of Alzheimer's Disease Reveal Neurovascular Defects, Altered Amyloid-β Homeostasis, and Deregulated Expression of Long Noncoding RNAs. 
  • Transthyretin sequesters amyloid beta protein and prevents amyloid formation. 
  • Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic. 
  • Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. 
  • Use of florbetapir-PET for imaging beta-amyloid pathology. 
  • Using N-Terminal Coordination of Cu(II) and Ni(II) to Isolate the Coordination Environment of Cu(I) and Cu(II) Bound to His13 and His14 in Amyloid-β(4-16). 
  • [Studying pathogenesis of Alzheimer's disease in a Drosophila melanogaster model: human APP overexpression in the brain of transgenic flies leads to deficit of the synaptic protein synaptotagmin]. 
  • mNos2 deletion and human NOS2 replacement in Alzheimer disease models. 
• 

  Keywords of People

  • Bowes Rickman, Catherine, George and Geneva Boguslavsky Distinguished Professor of Eye Research, Cell Biology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society